Medirom Healthcare Technologies Inc. Regains NASDAQ Compliance After Meeting Minimum Bid Price Requirement

Reuters
05 Jun
Medirom Healthcare Technologies Inc. Regains NASDAQ Compliance After Meeting Minimum Bid Price Requirement

New York, June 5, 2025 - MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a Japan-based holistic healthcare company, has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company had received a notification from Nasdaq on February 27, 2025, regarding its non-compliance with the rule, which mandates a minimum closing bid price of $1.00 per share for listed securities. MEDIROM was given until August 26, 2025, to meet this requirement. As of June 4, 2025, the company confirmed that its American Depositary Shares had maintained a closing bid price of $1.00 or more for 10 consecutive business days, from May 20 to June 3, 2025. Consequently, Nasdaq has informed MEDIROM that it is now in compliance with the listing rule, closing the matter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medirom Healthcare Technologies Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10